ClinicalTrials.gg
RecruitingNCT07007676INTELLECTUpdated Sep 8, 2026

Effect of Continuous Glucose Monitoring System on Glycemic Control in Non-insulin-Treated Elderly People With Type 2 Diabetes

An interventional study of real-time CGM in Diabetes Mellitus Type 2, sponsored by Shanghai 6th People's Hospital. Recruiting at 21 sites in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Shanghai 6th People's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital — 6 open to participants now, 7 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Shanghai 6th People's Hospital.

Started
2025
with 3 others
No phase
7 of 11
3 open now
Registered
7th of 11
by date

Among the 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital, this one is one of 4 that started in 2025, is one of 7 with no phase, and was the 7th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if continuous glucose monitoring system works to improve glucose control in non-insulin-treated older adults with type 2 diabetes. The main questions it aims to answer are:

  • Dose the use of continuous glucose monitoring system improve glucose control in older adults with type 2 diabetes treated with oral antidiabetic drugs only?
  • Dose the use of continuous glucose monitoring system affect psychological outcomes in older adults with type 2 diabetes treated with oral antidiabetic drugs only? Researchers will compare continuous glucose monitoring to standard blood glucose monitoring to see if continuous glucose monitoring works better in glucose management.

Participants will:

  • Wear continuous glucose monitoring every 2 months or standard blood glucose monitoring for 6 months
  • Visit the clinic once every 2 months for follow-up
  • Keep a diary of their blood glucose when continuous glucose monitoring was not used
03

Conditions studied

  • Diabetes Mellitus Type 2

Keywords

  • continuous glucose monitoring
  • non-insulin-treated
  • type 2 diabetes in the elderly
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 60 years at the time of screening;
  • Diagnosed with type 2 diabetes mellitus;
  • Treated with two or more oral antidiabetic drugs with a stable medication regimen (medication classes) during the 3 months prior to entry;
  • Suboptimal glycemic control, defined as ≥ 7.5% and ≤ 10% at screening or within 30 days prior to screening visit;
  • Has a smart phone compatible with CGM and BGM systems;
  • Willing and able to provide written ;
  • At least 240 hours (10 out of 14 days) of sensor glucose data from the blinded CGM pre-randomization phase.

Exclusion criteria

Exclusion Criteria:

  • Use of insulin or Glucagon-Like Peptide-1 (GLP-1) receptor agonists within 3 months prior to screening;
  • Use of any CGM device within 3 months prior to screening;
  • Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area;
  • Considered unsuitable for participation by the investigators, including but not limited to individuals with dementia, psychiatric disorders, extreme visual or hearing impairment that would impair ability to use real-time CGM assessed;
  • Planned surgery or other procedures within the next 6 months that may interfere with scheduled follow-up visits;
  • Current or anticipated acute uses of (oral, injectable, or IV), that will affect glycemic control;
  • Estimated (eGFR) \< 30 ml/min/1.73m2;
  • Participation in any other clinical trial within 3 month prior to screening, or concurrently enrolled, or planning to participate in another trial during the study period.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    Real-time Continuous Glucose Monitoring (CGM) group

    CGM group participants will be asked to use a CGM sensor every 2 months. Participants will be instructed to use the sensor. In addition, participants will be advised to check the blood glucose when symptoms or expectations do not match the CGM reading.

    Device: real-time CGM

  • No intervention
    Blood Glucose Meter (BGM) group

    BGM group participants will be asked to use a study blood glucose meter with test strips for a fingerstick blood glucose check with a recommendation of 2 times a week. Participants will be permitted to check a fingerstick glucose as many times a week as they choose.

Interventions

  • Devicereal-time CGM

    real-time CGM can provide real-time tracking of glucose levels, and offer glucose trend graphs and user-configurable low and high glucose alerts.

    Also known as: rtCGM, RT-CGM

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Change in HbA1c from baseline to 24 weeks

    Time frame: 24 weeks from baseline

Secondary outcomes

  1. Time in range of 70-180 mg/dL

    A treatment group comparison of percentage of time spent in glucose range between 70 and 180 mg/dL measured by CGM

    Time frame: 24 weeks from baseline

  2. Time below range of 70 mg/dL

    A treatment group comparison of percentage of time spent in glucose range below 70 mg/dL measured by CGM

    Time frame: 24 weeks from baseline

  3. Time above range of 180 mg/dL

    A treatment group comparison of percentage of time spent in glucose range above 180 mg/dL measured by CGM

    Time frame: 24 weeks from baseline

  4. Glucose coefficient of variability

    A treatment group comparison of glucose coefficient of variability measured by CGM

    Time frame: 24 weeks from baseline

  5. Mean glucose

    A treatment group comparison of the mean glucose measured by CGM

    Time frame: 24 weeks from baseline

Other outcomes

  1. HbA1c <7.0%

    Percentage of subjects with A1C less than 7%

    Time frame: 24 weeks from baseline

  2. Reduction in HbA1c ≥0.5%

    Percentage of subjects with a reduction in A1C greater than or equal to 0.5%

    Time frame: 24 weeks from baseline

  3. Rate of hypoglycemia events per week

    Hypoglycemia event was defined as 15 consecutive minutes with a sensor glucose value \<70 mg/dL

    Time frame: 24 weeks from baseline

  4. Time in tight range of 70-140 mg/dL

    A treatment group comparison of the percentage of time spent in glucose range between 70 and 140 mg/dL measured by CGM

    Time frame: 24 weeks from baseline

  5. Glycemia risk index (GRI)

    A treatment group comparison of the glycemia risk index measured by CGM. Glycemia risk index (GRI) was calculated according to the following equation: GRI = (3.0×VLow) + (2.4×Low) + (1.6×VHigh) + (0.8×High).

    Time frame: 24 weeks from baseline

  6. Glucose standard deviation

    A treatment group comparison of the glucose standard deviation measured by CGM

    Time frame: 24 weeks from baseline

  7. Days to initiate inulin treatment

    A treatment group comparison of the days to initiate inulin treatment during study period

    Time frame: 24 weeks from baseline

  8. Change in the scores of psychological-related questionnaires

    Psychological-related events were measured by Diabetes Distress Scale and Patient Health Questionnaire-8 items.

    Time frame: 24 weeks from baseline

  9. Change in the score of blood glucose monitoring satisfaction questionnaire

    Change in the score of blood glucose monitoring satisfaction questionnaire from 24 weeks from baseline

    Time frame: 24 weeks from baseline

07

Study locations

21 of 21 sites recruiting
  • Shenzhen Jiangangshan Health Service Center
    Shenzhen, Guandong 518000, China
    Recruiting
  • Shenzhen Fifth Avenue Health Service Station
    Shenzhen, Guangdong 518000, China
    Recruiting
  • Shenzhen Haifu Health Service Station
    Shenzhen, Guangdong 518000, China
    Recruiting
  • Shenzhen Haile Huafu Health Service Station
    Shenzhen, Guangdong 518000, China
    Recruiting
  • Shenzhen Haiyu Health Service Station
    Shenzhen, Guangdong 518000, China
    Recruiting
  • Shenzhen Jiaan Health Service Station
    Shenzhen, Guangdong 518000, China
    Recruiting
  • Shenzhen Jiari Mingju Health Service Station
    Shenzhen, Guangdong 518000, China
    Recruiting
  • Shenzhen Xinan Lake Health Service Station
    Shenzhen, Guangdong 518000, China
    Recruiting
  • Shenzhen Xingdong Health Service Station
    Shenzhen, Guangdong 518000, China
    Recruiting
  • Shenzhen Zhongliang Chuangxin Health Service Station
    Shenzhen, Guangdong 518000, China
    Recruiting
  • Guantian Community Health Service Station
    Shenzhen, Guangdong 518108, China
    Recruiting
  • Huiyu Mingdu Community Health Service Station
    Shenzhen, Guangdong 518108, China
    Recruiting
  • Langxin Community Health Service Station
    Shenzhen, Guangdong 518108, China
    Recruiting
  • Luozu Community Health Service Center
    Shenzhen, Guangdong 518108, China
    Recruiting
  • Shuitian Health Service Center
    Shenzhen, Guangdong 518108, China
    Recruiting
  • Tianbao Community Health Service Center
    Shenzhen, Guangdong 518108, China
    Recruiting
  • Shenzhen Buxin Community Health Service Center
    Shenzhen, Guangdong, China
    Recruiting
  • Shenzhen Dalang Community Health Service Center
    Shenzhen, Guangdong, China
    Recruiting
  • Shenzhen Haihua Community Health Service Center
    Shenzhen, Guangdong, China
    Recruiting
  • Shenzhen Haile Community Health Service Station
    Shenzhen, Guangdong, China
    Recruiting
    • Jing Liu, Dr. · Contactliuj@126.com · +86 755 2784 2711
  • Shenzhen Pingzhou Community Health Service Center
    Shenzhen, Guangdong, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Feb 2027, 19 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 19 months is close to that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jun 6, 2025
StartActual
Jul 14, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Jun 30, 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07007676
Lead sponsor
Shanghai 6th People's Hospital
Collaborators
Shenzhen Center for Chronic Disease Control, Shenzhen Baoan District People's Hospital, Shenzhen Haile Community Health Service Station, Shenzhen Buxin Community Health Service Center, Shenzhen Dalang Community Health Service Center, Shenzhen Haihua Community Health Service Center, Shenzhen Pingzhou Community Health Service Center, Shenzhen Fifth Avenue Health Service Station, Shenzhen Haifu Health Service Station, Shenzhen Haile Huafu Health Service Station, Shenzhen Haiyu Health Service Station, Shenzhen Jiaan Health Service Station, Shenzhen Jiari Mingju Health Service Station, Shenzhen Jiangangshan Health Service Center, Shenzhen Xinan Lake Health Service Station, Shenzhen Xingdong Health Service Station, Shenzhen Zhongliang Chuangxin Health Service Station, Shenzhen Guantian Community Health Service Station, Shenzhen Huiyu Mingdu Community Health Service Station, Shenzhen Langxin Community Health Service Station, Shenzhen Luozu Community Health Service Center, Shenzhen Tianbao Community Health Service Center, Shenzhen Shuitian Health Service Center
Responsible party
Jian Zhou (Professor, Chief Physician, Deputy Director, Shanghai 6th People's Hospital) — Principal investigator
First posted
Jun 6, 2025
Start date
Jul 14, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Sep 8, 2026

Study contacts

Jian Zhou, Prof., Dr., Ph.D
Contact
zhoujian@sjtu.edu.cn
86-21-64369181
Yaxin Wang, Dr.
Contact
wangyaxin2019@126.com
Jian Zhou, Prof., Dr., Ph.D
principal investigator · Shanghai 6th People's Hospital
Xiaobing Wu, Ph.D
principal investigator · Shenzhen Center for Chronic Disease Control

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion